News
Mallinckrodt & Silence Therapeutics to develop RNAi therapeutics
Mallinckrodt will work with Silence Therapeutics under a new collaboration to develop and commercialise novel RNA2 interference (RNAi) therapeutics for complement-mediated diseases.
The agreement will...
New CRISPR license framework to encourage innovation
MilliporeSigma and the Broad Institute of MIT and Harvard will together offer non-exclusive licenses to CRISPR IP under their respective control for use in...
AUM licenses first-in-class targeted cancer therapy
Singapore’s AUM Biosciences (AUM) is licensing Inflection Biosciences first-in-class PIM/PI3K/mTOR inhibitors.
Under the agreement, AUM will develop, manufacture and commercialise the inhibitors.
Known as the IBL-300...
